ACADIA Competitors
| ACAD Stock | USD 23.56 0.10 0.43% |
ACADIA Pharmaceuticals vs Lipocine Correlation
Weak diversification
The correlation between ACADIA Pharmaceuticals and LPCN is 0.39 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding ACADIA Pharmaceuticals and LPCN in the same portfolio, assuming nothing else is changed.
Moving together with ACADIA Stock
Moving against ACADIA Stock
| 0.65 | IMRN | Immuron Ltd ADR | PairCorr |
| 0.64 | EVGN | Evogene | PairCorr |
| 0.6 | KRRO | Frequency Therapeutics | PairCorr |
| 0.55 | GNLX | Genelux Common | PairCorr |
| 0.52 | JUMP | Leveljump Healthcare Corp | PairCorr |
ACADIA Pharmaceuticals Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between ACADIA Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of ACADIA and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of ACADIA Pharmaceuticals does not affect the price movement of the other competitor.
| 0.85 | -0.26 | 0.74 | -0.87 | GOVX | ||
| 0.85 | -0.1 | 0.64 | -0.73 | BLRX | ||
| -0.26 | -0.1 | 0.2 | 0.4 | THAR | ||
| 0.74 | 0.64 | 0.2 | -0.57 | AIMD | ||
| -0.87 | -0.73 | 0.4 | -0.57 | LPCN | ||
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between ACADIA Stock performing well and ACADIA Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze ACADIA Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| GOVX | 5.33 | (2.41) | 0.00 | (0.83) | 0.00 | 9.38 | 42.89 | |||
| BLRX | 2.59 | (0.27) | 0.00 | (0.19) | 0.00 | 5.20 | 13.04 | |||
| THAR | 5.48 | 0.50 | 0.08 | 0.40 | 5.92 | 11.55 | 40.06 | |||
| AIMD | 4.50 | (0.89) | 0.00 | (0.22) | 0.00 | 12.30 | 38.73 | |||
| LPCN | 5.03 | 2.00 | 0.39 | (14.40) | 3.32 | 15.95 | 33.09 |
Cross Equities Net Income Analysis
Compare ACADIA Pharmaceuticals and related stocks such as GeoVax Labs, BioLineRx, and Tharimmune Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GOVX | 36.7 M | (2.3 M) | (2.1 M) | (2.3 M) | (2.7 M) | (2.7 M) | (3.3 M) | (2.2 M) | (2.6 M) | (2.4 M) | (2.9 M) | (18.5 M) | (14 M) | (26 M) | (25 M) | (22.5 M) | (21.4 M) |
| BLRX | (32.1 M) | (13.2 M) | (20.4 M) | (17.6 M) | (10.2 M) | (14.4 M) | (15.8 M) | (24.4 M) | (23 M) | (25.4 M) | (30 M) | (27.1 M) | (25 M) | (60.6 M) | (9.2 M) | (8.3 M) | (8.7 M) |
| THAR | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (2.4 M) | (2.2 M) | (8.5 M) | (9.3 M) | (12.2 M) | (11 M) | (10.4 M) |
| AIMD | (300 K) | (1.3 M) | (650.8 K) | (622.6 K) | (622.6 K) | (521.9 K) | (670 K) | (617.4 K) | (1.3 M) | (1.6 M) | (1.5 M) | (3.9 M) | (14 M) | (13.8 M) | (14.9 M) | (13.4 M) | (12.7 M) |
| LPCN | (5.2 K) | (5.2 K) | (76.7 K) | (10.6 M) | (20.4 M) | (18.2 M) | (19 M) | (21 M) | (11.7 M) | (13 M) | (21 M) | (634.4 K) | (10.8 M) | (16.4 M) | 8.4 K | 7.5 K | 7.9 K |
ACADIA Pharmaceuticals and related stocks such as GeoVax Labs, BioLineRx, and Tharimmune Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in ACADIA Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of ACADIA Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.ACADIA Pharmaceuticals Competitive Analysis
The better you understand ACADIA Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, ACADIA Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across ACADIA Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
ACADIA Pharmaceuticals Competition Performance Charts
Five steps to successful analysis of ACADIA Pharmaceuticals Competition
ACADIA Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by ACADIA Pharmaceuticals in relation to its competition. ACADIA Pharmaceuticals' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of ACADIA Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact ACADIA Pharmaceuticals' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to ACADIA Pharmaceuticals, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your ACADIA Pharmaceuticals position
In addition to having ACADIA Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Long/short ETFs Thematic Idea Now
Long/short ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Long/short ETFs theme has 33 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Long/short ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out ACADIA Pharmaceuticals Correlation with its peers. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Will Biotechnology sector continue expanding? Could ACADIA diversify its offerings? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ACADIA Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.128 | Earnings Share 1.55 | Revenue Per Share | Quarterly Revenue Growth 0.113 | Return On Assets |
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that ACADIA Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether ACADIA Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, ACADIA Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.